Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 11INDUSTRY 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 99Tumor-Agnostic 6Other solid neoplasm 6Gastrointestinal 4CNS 4Head & Neck 3Breast 2Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Brain Neoplasms 3Meningeal Carcinomatosis 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × osimertinib × CNS × Clear all
NCT07361705 2026-01-23

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

Alpha Biopharma (Jiangsu) Co., Ltd.

Phase 1 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT07206498 2025-11-28

WAYWIN103

Wayshine Biopharm, Inc.

Phase 1/2 Recruiting
48 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05948813 2024-11-21

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

TYK Medicines, Inc

Phase 2 Recruiting
420 enrolled
CNS

Brain Neoplasms

NCT02228369 2021-01-05

BLOOM

AstraZeneca

Phase 1 Completed
108 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡